Neogenomics INC Form 4 insider transactions

Director Alison L. Hannah reports the release of restricted stock units and subsequent acquisition of common stock in Neogenomics.

Director Gunn Neil reported the release of restricted stock units and subsequent ownership of common stock in Neogenomics Inc.

Director Elizabeth Floegel reported the release of restricted stock units and subsequent ownership of common stock in Neogenomics.

Alicia Olivo, General Counsel of Neogenomics, reports the surrender of shares to cover tax obligations and details of stock options and restricted stock units.

Director Anthony P. Zook reports acquisition of stock options and restricted stock units in Neogenomics.

Director Lynn A. Tetrault reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Director David Brian Perez reports acquisition of Neogenomics stock options and disposition of common stock.

Director Michael Aaron Kelly reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Director Stephen M Kanovsky reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Director Alison L. Hannah reports acquisition of stock options and restricted stock units in Neogenomics.

Director Neil Gunn reports acquisition of Neogenomics stock options and restricted stock units.

Director Elizabeth Floegel reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Alicia C. Olivo, General Counsel of Neogenomics, sold 1,049 shares of common stock at a price of $15.74 on May 15, 2024.

CEO Christopher Smith reports acquisition and disposition of NeoGenomics stock and derivative securities, including restricted stock units and stock options.

Alicia Olivo, General Counsel of Neogenomics, reports the vesting of restricted stock units and subsequent tax withholding, impacting her beneficial ownership of company stock.

Warren Stone, Chief Commercial Officer of Neogenomics, reports the vesting and disposal of restricted stock units to cover tax obligations, along with the acquisition of additional stock options and units.

Chief Financial Officer Jeffrey Scott Sherman reported the acquisition and disposal of Neogenomics Inc. stock and derivative securities.

Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reported the vesting of restricted stock units and associated tax withholding, along with holdings of stock options and performance stock units.

Chief Commercial Officer Warren Stone reports acquisition of stock options and restricted stock units in Neogenomics.

Alicia C. Olivo, General Counsel of Neogenomics, filed a Form 4 detailing changes in her beneficial ownership, including stock vesting and tax obligation fulfillment.

Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reports the acquisition of stock options and restricted/performance stock units.

Chief Accounting Officer Greg D. Aunan reports acquisition and disposal of Neogenomics stock and derivative securities.

Director Lynn A. Tetrault sold 6,112 shares of Neogenomics Inc. on March 4, 2024, at a price of $15.9651 per share.

Warren Stone, President of Clinical Services at Neogenomics, reports the acquisition of stock options, restricted stock units, and performance stock units.

Alicia C. Olivo, General Counsel of Neogenomics, reports the acquisition of stock options and restricted/performance stock units.

Chief Financial Officer Jeffrey Scott Sherman reports the acquisition of stock options, restricted stock units, and performance stock units in Neogenomics Inc.

Neogenomics CEO Christopher M. Smith reports the acquisition of stock options, restricted stock units, and performance stock units.

Melody Harris, President of Enterprise Operations at Neogenomics, reports the grant of stock options, restricted stock units, and performance stock units, along with existing holdings.

Vishal Sikri, President of Advanced Diagnostics at Neogenomics, reports the acquisition of stock options and restricted/performance stock units.